Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $7.2900 (5.65%) ($7.2900 - $7.2900) on Wed. Mar. 31, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.5% (three month average) | RSI | 27 | Latest Price | $7.2900(5.65%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.8% a day on average for past five trading days. | Weekly Trend | HTBX declines -8.9% a week on average for past two weeks. | Market Behavior | Rotation from value to growth for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) XBI(40%) ARKG(39%) ARKK(35%) IBB(35%) IPO(33%) | Factors Impacting HTBX price | HTBX will decline at least -4.25% in a week (0% probabilities). VIXM(-25%) VXX(-21%) IGOV(-16%) UUP(-13%) XLU(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.25% (StdDev 8.5%) | Hourly BBV | 0.4 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-6.51(-189.3%) | Resistance Level | $8.05 | 5 Day Moving Average | $7.29(0%) | 10 Day Moving Average | $7.71(-5.45%) | 20 Day Moving Average | $8.05(-9.44%) | To recent high | -41.9% | To recent low | 36.1% | Market Cap | $802m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |